Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib

Kenta Yokoi(Shinshu University), Shinichi Miyagawa(Shinshu University)
Oncology Reports
December 13, 2017
Cited by 39


Related Papers